“I nearly lost my life to septic shock because I didn’t know the signs and symptoms” 💬 🎥 On this World Sepsis Day, discover Katy Grainger’s moving story. In September 2018, her life was turned upside-down when she nearly died from septic shock because of a small, infected cut on her thumb. Because of sepsis, she now lives as a double below-knee amputee who also lost the tips of most of her fingers. ⏳ In the fight against #Sepsis, early recognition and rapid diagnosis are essential for early patient management.
关于我们
Pioneering Diagnostics A world leader in the field of in vitro diagnostics for more than 60 years, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2020, revenues reached €3.1 billion, with over 90% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software, services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the Euronext Paris stock market. Symbol: BIM – ISIN Code: FR0013280286 Reuters: BIOX.PA/Bloomberg: BIM.FP
- 网站
-
https://www.biomerieux.com
bioMérieux的外部链接
- 所属行业
- 生物技术研究
- 规模
- 超过 10,001 人
- 总部
- Marcy-l'Étoile，Auvergne-Rhône-Alpes
- 类型
- 上市公司
- 创立
- 1963
- 领域
- in vitro diagnostics、infectious diseases、reagents、automated instruments、medical analysis、cosmetics、pharmaceutical、industries、healthcare associated infections、molecular biology、microbiology、immunoassays、antimicrobial stewardship、rapid diagnostics、food safety、veterinary diagnostics、blood bank和sepsis
地点
bioMérieux员工
动态
-
🤒 In 2018, 22-year-old Leticia de Oliveira Batista presented to the emergency department of a São Paulo hospital with fever, a sore throat, a runny nose, and very low blood pressure. She was given vasopressors, but quickly lost consciousness. That was the beginning of a long nightmare… Leticia was diagnosed with community-acquired pneumonia caused by Streptococcus pyogenes, which had rapidly developed into severe #sepsis. 👉 Discover her story on our blog: http://spkl.io/6048f8Rd6 #SepsisAwareness
-
-
🗣️ We had the privilege of interviewing Lord Jim O’Neill, renowned economist and leader of the landmark review on #AntimicrobialResistance (AMR) published in 2016. In this insightful conversation, Lord O’Neill shares his thoughts on the economic impact of AMR, the limited progress made over the past eight years, in particular "in applying affordable, quick, state-of-the-art diagnostics to know whether people need an antibiotic or not." He stresses the need for massive awareness and policy focus, akin to the climate change movement. 📅 On September 26th United Nations General Assembly will convene a High-Level Meeting on AMR It is imperative that we leverage this milestone to continue to elevate the issue to the top of the global public health agenda. Through this we must also ensure we are strengthening the utilization of diagnostics to support patients and curb AMR.
-
💡 To enhance our commitment to employee #feedback, all 14,600 bioMérieux team members were invited to participate in a Global Engagement Survey this May. Every two years, they are encouraged to express their feelings and expectations about their employee experience and offer ideas on how to impact it. This year’s high participation rate (86%) reflects the strong engagement and dedication of our teams. 🙌 🎯 This initiative is part of our continuous improvement approach, with the goal of having bioMérieux in the Top 25% of « Healthcare - Pharmaceuticals, Biotechnology & Life Sciences industry ». By fostering open dialogues within teams, the surveys serve as a valuable approach tailored to global and local needs, enabling us to listen, understand, and act to improve our team members’ life at bioMérieux. #WeArebioMérieux
-
-
As scientists continue to study COVID-19 and its variants, they are gaining valuable insights into how viruses are transmitted and how they can progress into life-threatening conditions such as #sepsis. 📝 Visit our Living Diagnostics blog to learn more about viral sepsis and why diagnostics are critical in distinguishing between infections for better patient outcomes. 👉 http://spkl.io/6048fBSIq
-
-
📢 We are announcing today our first-half 2024 results. We delivered a solid performance with €1,902m as of June 30, with an organic growth of +9.9% like-for-like. Contributive operating income before non-recurring items (CEBIT) reached €306 million for the first half of the year, representing a steady +20% like-for-like evolution versus H1 2023. Our growth is driven by molecular biology (BIOFIRE® respiratory and non-respiratory panels, BIOFIRE® SPOTFIRE®), microbiology and industrial applications. As a result, our 2024 full year guidance has been revised upward: sales expected to grow organically by +8% to +10% (versus 6% to 8% initially). 📰 Read the full press release: https://lnkd.in/eHW79QZ8 #PioneeringDiagnostics
-
-
In advance of the United Nations High-Level Meeting on #AntimicrobialResistance in September, the AMR Industry Alliance officially called on the UN and its member states work with the private sector “to commit to and advance bold, coordinated action on AMR”. 🗣️ We asked James Anderson, Alliance Board Chair, to discuss the urgent actions required to address AMR and the contributions of the life-sciences industry. It is only through collaborative efforts that we will make significant progress against AMR. Read his insights in our latest blog article ⤵️ https://lnkd.in/gzP75BF9
-
📢 Exciting News from La Balme-les-Grottes in France! LaBNext, our new state-of-the-art R&D building, has been inaugurated on September 2nd. This cutting-edge equipment symbolizes our pioneering spirit and commitment to advancing public #health. 🆕 This 2000-m² microbiology R&D space is equipped with the latest technologies in phenotypic analysis, proteomics and genomics. Here, our searchers work on new diagnostic solutions to help fight infectious diseases. A special thanks to our teams for their dedication and #innovation! Together, we are shaping the future of diagnostics and investing in long-term health solutions for patients worldwide. 👉 Take a video tour of LaBNext on: http://spkl.io/6046fBkHn #PioneeringDiagnostics
-
-
-
-
-
+2
-
-
🌍🦟On the eve of #WorldMosquitoDay, we emphasize the critical role of diagnostics in managing arboviruses like Chikungunya and Dengue. Accurate and timely methods are crucial for early detection, effective treatment, and outbreak control. 🔎 Explore our new monographs to enhance your knowledge and improve patient management: 👉 http://spkl.io/60424hN3y
-
-
Congratulations to our partner SpinChip Diagnostics ASA for the publication of fantastic clinical and analytical performance results of its POC high sensitivity cardiac Troponin assay in the renowned Journal of the American College of Cardiology (JACC Journals). 👉 The conclusion of the JACC editorial is self-speaking: “In conclusion, the hs-cTnI-SPINCHIP POCT assay offers a promising advancement in the rapid and accurate diagnosis of MI, with significant potential to improve patient outcomes and streamline workflow in the ED." 📰 Read SpinChip latest press release to learn more: https://lnkd.in/ejGdvTyY
PRESS RELEASE - SpinChip announces publication of the APACE study in the Journal of the American College of Cardiology (JACC) - SpinChip
https://spinchip.no